247 related articles for article (PubMed ID: 25668238)
1. Topical Mineralocorticoid Receptor Blockade Limits Glucocorticoid-Induced Epidermal Atrophy in Human Skin.
Maubec E; Laouénan C; Deschamps L; Nguyen VT; Scheer-Senyarich I; Wackenheim-Jacobs AC; Steff M; Duhamel S; Tubiana S; Brahimi N; Leclerc-Mercier S; Crickx B; Perret C; Aractingi S; Escoubet B; Duval X; Arnaud P; Jaisser F; Mentré F; Farman N
J Invest Dermatol; 2015 Jul; 135(7):1781-1789. PubMed ID: 25668238
[TBL] [Abstract][Full Text] [Related]
2. Re-Epithelialization of Pathological Cutaneous Wounds Is Improved by Local Mineralocorticoid Receptor Antagonism.
Nguyen VT; Farman N; Maubec E; Nassar D; Desposito D; Waeckel L; Aractingi S; Jaisser F
J Invest Dermatol; 2016 Oct; 136(10):2080-2089. PubMed ID: 27262545
[TBL] [Abstract][Full Text] [Related]
3. Effects of a multilamellar emulsion on glucocorticoid-induced epidermal atrophy and barrier impairment.
Ahn SK; Bak HN; Park BD; Kim YH; Youm JK; Choi EH; Hong SP; Lee SH
J Dermatol; 2006 Feb; 33(2):80-90. PubMed ID: 16556273
[TBL] [Abstract][Full Text] [Related]
4. A single-center, double-blind, randomized trial of the atrophogenic effects of fluocinonide cream 0.1% versus clobetasol propionate cream 0.05% in participants with corticosteroid-responsive dermatoses.
Uliasz A; Zeichner J; Soung J; Wong V; Lebwohl M
Cutis; 2008 Jun; 81(6):517-9. PubMed ID: 18666395
[TBL] [Abstract][Full Text] [Related]
5. Mineralocorticoid receptor blockade improves glucocorticoid-induced skin atrophy but partially ameliorates anti-inflammatory actions in an irritative model in human skin explants.
Boix J; Nguyen VT; Farman N; Aractingi S; Pérez P
Exp Dermatol; 2018 Feb; 27(2):185-187. PubMed ID: 29178328
[TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid Receptor Antagonists-A New Sprinkle of Salt and Youth.
Stojadinovic O; Lindley LE; Jozic I; Tomic-Canic M
J Invest Dermatol; 2016 Oct; 136(10):1938-1941. PubMed ID: 27664711
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial.
Cossmann M; Welzel J
Br J Dermatol; 2006 Oct; 155(4):700-6. PubMed ID: 16965418
[TBL] [Abstract][Full Text] [Related]
8. Topical Administration of Spironolactone-Loaded Nanomicelles Prevents Glucocorticoid-Induced Delayed Corneal Wound Healing in Rabbits.
Dahmana N; Mugnier T; Gabriel D; Kaltsatos V; Bertaim T; Behar-Cohen F; Gurny R; Kalia YN
Mol Pharm; 2018 Mar; 15(3):1192-1202. PubMed ID: 29397733
[TBL] [Abstract][Full Text] [Related]
9. Topical clobetasol for the treatment of toxic epidermal necrolysis: study protocol for a randomized controlled trial.
Wilken R; Li CS; Sharon VR; Kim K; Patel FB; Patel F; Maverakis E
Trials; 2015 Aug; 16():374. PubMed ID: 26297574
[TBL] [Abstract][Full Text] [Related]
10. Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities.
Kao JS; Fluhr JW; Man MQ; Fowler AJ; Hachem JP; Crumrine D; Ahn SK; Brown BE; Elias PM; Feingold KR
J Invest Dermatol; 2003 Mar; 120(3):456-64. PubMed ID: 12603860
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of putative hyalurosome platform in keratinocytes as a mechanism for corticosteroid-induced epidermal atrophy.
Barnes L; Ino F; Jaunin F; Saurat JH; Kaya G
J Invest Dermatol; 2013 Apr; 133(4):1017-26. PubMed ID: 23223147
[TBL] [Abstract][Full Text] [Related]
12. Topical hesperidin prevents glucocorticoid-induced abnormalities in epidermal barrier function in murine skin.
Man G; Mauro TM; Kim PL; Hupe M; Zhai Y; Sun R; Crumrine D; Cheung C; Nuno-Gonzalez A; Elias PM; Man MQ
Exp Dermatol; 2014 Sep; 23(9):645-51. PubMed ID: 24980072
[TBL] [Abstract][Full Text] [Related]
13. Action of topical thyroid hormone analogue, triiodothyroacetic acid in reversing glucocorticoid-induced skin atrophy in humans.
Yazdanparast P; Carlsson B; Oikarinen A; Risteli J; Lavin T; Faergemann J
Thyroid; 2006 Nov; 16(11):1157-62. PubMed ID: 17123343
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial.
Tosti A; Iorizzo M; Botta GL; Milani M
J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1243-7. PubMed ID: 17062039
[TBL] [Abstract][Full Text] [Related]
15. Spironolactone decreases the somatic signs of opiate withdrawal by blocking the mineralocorticoid receptors (MR).
Navarro-Zaragoza J; Laorden ML; Milanés MV
Toxicology; 2014 Dec; 326():36-43. PubMed ID: 25308750
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel in vitro test systems for the determination of glucocorticoid receptor ligand-induced skin atrophy.
Schoepe S; Schäcke H; Bernd A; Zöller N; Asadullah K
Skin Pharmacol Physiol; 2010; 23(3):139-51. PubMed ID: 20051715
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Mineralocorticoid Receptor Plays Beneficial and Adverse Effects in Skin and Mediates Glucocorticoid Responses.
Boix J; Sevilla LM; Sáez Z; Carceller E; Pérez P
J Invest Dermatol; 2016 Dec; 136(12):2417-2426. PubMed ID: 27464843
[TBL] [Abstract][Full Text] [Related]
18. Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.
Rogerson FM; Yao Y; Smith BJ; Fuller PJ
Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):704-9. PubMed ID: 15554912
[TBL] [Abstract][Full Text] [Related]
19. A novel mineralocorticoid receptor antagonist, 7,3',4'-trihydroxyisoflavone improves skin barrier function impaired by endogenous or exogenous glucocorticoids.
Lee H; Choi EJ; Kim EJ; Son ED; Kim HJ; Park WS; Kang YG; Shin KO; Park K; Kim JC; Kim SN; Choi EH
Sci Rep; 2021 Jun; 11(1):11920. PubMed ID: 34099793
[TBL] [Abstract][Full Text] [Related]
20. Topical Applications of a Heparinoid-Containing Product Attenuate Glucocorticoid-Induced Alterations in Epidermal Permeability Barrier in Mice.
Wen S; Wu J; Ye L; Yang B; Hu L; Man MQ
Skin Pharmacol Physiol; 2021; 34(2):86-93. PubMed ID: 33652434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
